Peregrine Pharmaceuticals, Inc. today reported the issuance of a U.S. patent that further strengthens the company's intellectual property leadership in the field of phospholipid-targeting agents for the treatment of life-threatening diseases.
The details can be read here.
No comments:
Post a Comment